The immunotoxicologic effects of drugs on host defense have been studied widely using various animal models of infection. Here we describe a new approach to testing host defense by using a single organism ( Candida albicans ) in CBA/J mice. The model is configured to test 3 effector systems via different routes of inoculation to stimulate different effector arms of the immune response. Nonspecific immunity was evaluated by C. albicans colony-forming unit (CFU) count from the spleen at 2 hr (uptake) and &ge;22 hr (clearance) following intravenous inoculation. Cell-mediated immunity was assessed by CFU count from an intramuscular injection site 6 days postinoculation. Humoral immunity was assessed by anti-Candida antibody titer, following multiple subcutaneous immunizations with C. albicans. Finally, overall immunity was evaluated following intravenous injection using survival as the endpoint. Histopathological, immunohistochemical, and electron microscopic evaluation of selected tissues revealed the involvement of the expected cell types in the different effector systems. Several immunomodulatory drugs&mdash;dexamethasone, cyclosporine, liposomal muramyltripeptide phosphatidylethanolamine, and SK&F 105685&mdash;were evaluated in the C. albicans model. Dexamethasone impaired host defense against C. albicans by suppressing all endpoints measured. Similarly, cyclosporine showed broad immunosuppressive activity, with the exception of yeast uptake from the spleen. In contrast, muramyl tripeptide-phosphatidylethanolamine enhanced all but cell-mediated immunity to C. albicans. SK&F 105685 displayed both stimulatory and inhibitory effects on immune responses to the infection. Our studies demonstrate that a single organism-based approach can be a useful method for evaluating the immunological hazards of drugs on host resistance to infection.
INTRODUCTION
Over the past 2 decades there has been a growing awareness that immune dysfuntion can be an adverse event of therapeutic agents. Immunotoxicity is often in the form of immunosuppression but can also be expressed as inappropriate activation of the immune system. Identifying and characterizing immunological hazards induced by chemicals and drugs are major tasks for immunotoxicologists. For therapeutic agents designed to affect the immune system (immunomodulators) or drugs intended for use in patients with immunologic disorders (e.g., AIDS, asthma, rheumatoid arthritis), this task can be particularly difficult, because the pharmacologic activities and potential toxicities may be interrelated.
The most widely used approach to immunotoxicit) evaluation are tests reflected in the tiered approach of the National Toxicology Program (NTP) that is described ir the Food and Drug Administratioin Red Book II guides lines (1, 39) . Classic toxicologic parameters (i.e., orgar weights, histopathology, and hematology), accompaniec by ex vivo immune function assays (i.e., IgM response tc T cell-dependent antigen, mixed leukocyte reaction, an( natural killer cell activity in Tier 1 testing), are followec by further Tier 2 function testing when indications fol immunotoxicity are obtained in Tier 1. This is an effec tive approach to screening for immunologic effects on food additives, cosmetics, and environmental pollutants where human exposures are kept to a minimum, and fo drugs where there is no a priori reason to expect effect! on the immune system. However, the tiered approach ii problematic for testing immunologically active drugs. Because of their expected effects on immune function, relevance of effects in ex vivo assays to risk assessment is uncertain. It should also be stressed that, in concept, the detection of defects in the immune system, which may be considered a potential system, may remain dormant when the host is unchallenged. Therefore, we feel that a more targeted approach to immunotoxicity testing is warranted, placing importance on in vivo testing for effects on host defense.
Classically, the immune system has been thought of as 3 distinct systems: nonspecific immunity (NSI; the province of macrophages, polymorphonuclear leukocytes, and natural killer cells), cell-mediated immunity (CMI; the province of T lymphocytes), and humoral immunity (HI; the province of B lymphocytes) (53) . Numerous animal models have been developed and refined to detect effects of compounds on these effector systems. In general, these models focus on surrogate markers of immune function, that is, footpad swelling as a measure of CMI, clearance of inert particles from the blood as a measure of NSI, and the antibody response to a strong immunogen as a measure of HI. However, from our experience of evaluating immunomodulatory drugs, the measurement of surrogate markers of immune function may not be satisfactory to either regulatory agencies or physicians. For these audiences, the ultimate concern concentrates on potential adverse effects on host resistance. A widely accepted approach to evaluating effects on host defense against infection is to use a variety of organisms matched with different sensitive strains or species for which the different effector systems are believed to play an important role (i.e., infection with Herpes simplex virus for CMI, Streptococcus pneumoniae for HI, and Listeria monocytogenes for NSI). Survival and/or colony-forming unit (CFU) counts are often the major endpoint in these studies (16, 43) . This approach, however, is costly and time-consuming, requiring the testing laboratory to maintain skills with different organisms and test strains. Moreover, the kinetics of the established systems may not allow testing of a compound over a time frame relevant to other toxicity data, thus precluding intergration with data from the core toxicity studies in assessing hazard and risk.
To address these issues, we have developed an approach to immunotoxicity testing based on a combination of assays evaluating immune function in conjunction with host resistance to infection. Rather than using a variety of organisms and strains, we have developed a series of tests with a single infectious organism (Candida albicans) in a single host strain (CBA/J mice) designed to emphasize the contribution of the different effector arms of the immune network.
Candida albicans was chosen because systemic candidiasis in inbred mice closely resembles human candidiasis. Both cerebral and renal diseases are common in disseminated infections. The kidney is less efficient in eliminating the organisms compared to liver and spleen, and renal failure, associated with neutrophilic interstitial nephritis, is a common cause of mortality (11, 45) . In C. albicans infections, many factors appear important in the clearance of the organisms. Opsonization by complement is critical in reducing the initial fungal burden, but development of complement-independent, specific immune responses determines the ultimate outcome (40) . Similarly, while phagocytic cells play a dominant role in the early host response to systemic C. albicans infection (4, 63) , optimal phagocytosis is attained in association with antigen-driven immunological reactivity (6) , most likely due to activation of the cells by cytokines produced by different leukocytes. Moreover, studies on the role of cellmediated immunity in C. albicans infections using T cell-depleted mice indicate that T-cell deficiency increases mortality in the later stages of the infection (18, 30) . There is also evidence that protection against mild infection is mediated by a C. albicans-specific antibodies (5) . With this background indicating involvement of nonspecific immunity at the early stage, and cell-mediated and humoral immunity at the later stages of infection, we have developed a four-parameter (survival, spleen CFU, muscle CFU, and antibody titer) model of host resistance to C. albicans that allows evaluation of effects of immunomodulatory drugs on the overall host capacity to mount a response to pathogen challenge, inclusive of both nonspecific and specific immune interactions.
MATERIALS AND METHODS
Animals. Female mice CBA/J, C57BL/DBA2-Fl, and BALB/cJ (Jackson Memorial Laboratory, Bar Harbor, ME) were used at approximately 8-12 wk of age. Mice were infected with C. albicans by different routes: intravenously (iv) into a tail vein, intramuscularly (im) into the calf muscle, or subcutaneously (sc) in the flank. CBA/J mice only were treated with compounds according to Candida albicans Preparation. Candida albicans strain B311 (serotype A; ATCC 32354) organisms were grown as suspension cultures in Sabouraud dextrose broth for 22 hr at 24°C, aliquoted, and frozen at -70°C. For injection, organisms from frozen stocks were grown in Sabouraud dextrose broth for 22 hr at 24°C on a rotary shaker. The yeast cells were washed 3 times, then resuspended in phosphate-buffered saline, and quantified by hemacytometer in the presence of 0.02% methylene blue.
The number of viable yeasts in the innocula was verified by determination of CFUs on yeast-extract-protease-dextrose (YEPD) agar plates incubated overnight at 37°C. Typical CFU counts indicated an 80-90% yield of viable organisms in comparison to hemacytometer counts. Measurement of Survival. Survival of mice was followed after C. albicans was iv injected. Typically, 10 mice per group were infected and observed daily until day 30 . Mice that were moribund were sacrificed. These mice were counted as if they had died the next day. Percentage of survival and median survival time for each group were calculated.
Preparation of Spleen, Kidney, and Muscle Tissue for CFU Count. In the nonspecific immunity model, 5-6 mice per group were injected iv and 2, 22, 45, and 70 hr later spleens, and kidneys in some experiments, were removed and processed to determine C. albicans CFUs by quantitative culture. Tissues were collected into sterile plastic bags and placed on ice, suspended in 10 mL PBS, homogenized using a Stomacher 80 Laboratory Blender (Seward Medical, London, UK) for 60 sec. The suspension was diluted 100-fold and diluted 0.5 ml plated into 24-well tissue culture plate (Costar). YEPD agar was melted and then cooled to approximately 40°C, and 1 ml was added to each well. The plates were shaken to mix C. albicans suspension with the agar, allowed to solidify, and then incubated at 37°C overnight. CFUs for each tissue sample were determined in quadruplicate. In the cellmediated immunity model, 5-6 mice per group were injected with C. albicans im into the gastrocnemius muscle.
To characterize clearance of infection, 6 days after intramuscular injection, calf muscles were removed and processed for CFU determination as described for spleen tissue.
Immunization for Anti-Candida Antibody. In the humoral immunity model, mice were sc injected with C. albicans on days 1 and 8. On day 16, mice were bled to obtain serum for anti-Candida antibody determination by enzyme-linked immunosorbent assay (ELISA). Approximately 0.3-0.5 ml blood was collected from the vena cava and pooled within a group of 3-5 mice. Sera from pooled blood samples were stored at -70°C until tested by ELISA.
ELISA Procedure. Round-bottomed 96-well Linbro plates (Flow Laboratories, Inc., McLean, VA) were coated with C. albicans by adding 1.5 X 105 organisms per well in trypticase soybean broth and incubated at 37°C for 90 min. Culturing C. albicans in this manner induces germ tube formation and adherence to the wells (22) . Cells were fixed with 2% paraformaldehyde (200 jjLl/well) and then stored at 4°C overnight. The coated plate was washed twice with saline followed by rinsing with 2% bovine serum albumin (BSA), 20 mM glycine, and 2% Tween-20 in saline. Samples of serially diluted mouse serum along with positive and negative controls were added to triplicate wells (100 p.l/well) and incubated at 37°C for 45 min. After washing 3 times with 2% Tween-20 (100 ~,1/well), goat anti-mouse IgG conjugated with alkaline phosphatase (Zymed, San Francisco, CA) was added (100 unwell) and the plate was incubated at 37°C for 45 min. Following washing, enzyme substrate, para-nitrophenylphosphate (Sigma Chemical Co., St. Louis, MO) was added (100 pLl/well) and the plate was incubated at room temperature for about 30 min to develop a chromogenic reaction, which was stopped by adding 6 M NaOH (30 ~..1/well). Samples (100 pLl/well) were transferred into new 96-well flat-bottomed plates, and the optical density (OD) was read at 405 nm. Anti-Candida antibody detection is expressed as net OD (sample OD subtracted from buffer background).
Histopathology. Tissues from 5 mice per group injected with C. albicans by different routes were collected at various time points postinoculation and fixed in buffered formalin or Bouin's solution. Spleen, kidneys, lung, liver, and brain were collected 1, 2 and 6 days after intravenous inoculation. Calf muscle was collected 1, 3, and 6 days post-intramuscular injection, and the tissue at the site of subcutaneous injection was collected on days 1 and 8 after the first injection and on day 7 after the second injection. All tissues were stained with hematoxylin and eosin (H&E) and Grocott's methenamine silver.
To determine the extent of lymphocytic infiltration induced in the intramuscular model, muscle tissues were collected and fixed with Bouin's solution for 24 hr and embedded in paraffin at 56°C according to the method for immunohistochemical detection of T-cell subsets (67) . Immunohistochemistry was performed using the avidin-biotinylated horseradish peroxidase complex (ABC) method (BioTech Solutions, Santa Barbara, CA) with diaminobenzidine as chromogen. Anti-human CD3 (Dako, Carpinteria, CA), which crossreacts with murine CD3 (Dr. S. Rehm, personal communication), was used to detect mature T lymphocytes.
Preparation and Administration of Test Compounds. Dexamethasone (Sigma) was dissolved in saline and administered intraperitoneally (ip) at 50 mg/kg/day for 5 days as previously reported (31, 32) or as shown in Table  I . Cyclosporine (Cyclosporin A; Sandimmune, Sandoz, Basel, Switzerland) was suspended in olive oil and administered ip at 25 mg/kg/day every other day for a total of 3 or 4 doses (37) . Muramyl tripeptide-phosphatidylethanolamine (MTP-PE) in multilamellar phosphatidylglycerol liposomes (41 ) was prepared by dissolving 2 mg MTP-PE (lot number CGP 19835A; a generous gift of Ciba-Geigy, Basel, Switzerland) in chloroform-methanol and combining it in solution with 150 mg egg phosphatidylglycerol (Sigma) in a I-L round-bottomed flask. The dissolved drug/lipid was dried as a thin film under a stream of nitrogen on a rotary evaporator. resuspended with 8.5 ml of PBS at 50°C, and transferred to a conical tube containing several glass beads, and the mixture was vortexed at room temperature until homogeneous. Aliquots were frozen and stored at -70° C until thawed for injection. This procedure yields liposomal MTP-PE at a drug concentration of 0.25 mg/ml. Liposomal MTP-PE was administered at 2 mg/kg by intravenous injection every other day as described previously by Frazer-Smith et al (25) . SK&F 105685 (SmithKline Beecham, King of Prussia, PA), an azaspirane, was dissolved in PBS and administered as a daily intraperitoneal injection of 15 mg/kg for 14 days. Preliminary studies have shown that 15 mg/kg administered in this dosing regimen is the maximum tolerated dose of SK&F 105685; higher doses cause decreased body weight gain.
Statistical Analysis. Data are expressed as the median or meant SEM as indicated. The nonparametric Wilcoxon test was used to analyze survival data and Dunnett's t-test was used to analyze data for the other models of host defense. Any p values S 0.05 were accepted as statistically significant.
RESULTS

Survival Model
To determine which strain of mice and what inoculum of C. albicans should be used in this study, survival of CBA/J, BALB/cJ, and C57B6/DBA2-Fl mice systemically infected with C. albicans were compared. As illustrated in Fig. 1 , CBA/J mice were the most sensitive strain tested. Inoculation with 5 X 106, 1 X 106, and 5 X 105 C. albicans resulted in a median survival time of 2, 6, and 9 days, respectively. C57B6/DBA2-Fl mice were relatively resistant to the infection because median survival time following infection with 1 X 106 C. albicans was approximetely 14 days. Sensitivity of BALB/cJ mice was greater than C57B6/DBA2-Fl but lower than CBA/J mice. Because we wished to work in a system that would detect either increased or decreased median survival times in the context of a 14-day study, CBA/J mice were chosen as the suitable strain in the model of the host defense against C. albicans infection. In multiple experiments, the median survival time using CBA/J mice and a 1 X 106 inoculum of C. albicans was established as 6 ± 2 days.
Histologically, infection was manifest by purulent interstitial nephritis on day 1. Although brain sections stained positive for Candida on day 1, purulent meningoencephalitis was generally not recognized until day 2 postinoculation. Brain and renal lesions progressed in severity, and by day 6 they were determined to be the cause of significant morbidity and mortality. Organisms were still present in brain and renal lesions on day 6. Neither lesions nor organisms were present in lung, spleen, or liver from 24 to 144 hr postinoculation.
Effect of Immunosuppressive and Immunostimulating Compounds in the Survival Model
The results of the survival studies are shown in Fig. 2 . As expected, treatment of CBA/J mice with the immunosuppressive drugs dexamethasone and cyclosporine FiG. l.-Survival of 3 strains of mice after intravenous injections with C. albicans B311 at nominal 0.5, 1, and 5 x 106 organisms per inoculation, using CBA/J and BALB/cJ strains (10 mice/group/inoculum). C57BL6/DBA2-F1 mice (10/group) were inoculated with 1 X 106 organisms only. Inocula of C. albicans were prepared as described in Materials and Methods. significantly decreased (p < 0.05) median survival time by 50%, from approximately 7 to 3.5 days ( Fig. 2A ). In contrast, treatment with liposomal MTP-PE and SK&F 105685 increased median survival time of infected mice from approximately 6 to 12 (p < 0.05) and from 6 to 10 (p > 0.05) days, respectively (Fig. 2B) . These data indicate that that survival rate in an acute systemic infection with C. albicans is a sensitive measure of changes in immune status of the host exposed to immunomodulatory compounds. To further characterize effects of different classes of drugs on host defense, 3 effector mechanism-based models of the immune response to C. albicans infections were evaluated.
Nonspecific Immunity Model
Mice challenged iv with C. albicans were evaluated for yeast colonization in tissues. Kinetics of yeast growth in the spleen was determined by ex vivo culture and CFU counts. As shown in Fig. 3 , C. albicans could be recovered in the spleen within 15 min after intravenous inoculation, indicating a rapid uptake of organisms by the spleen. The number of C. albicans CFUs did not change significantly between 15 min and 2 hr, but decreased CFUs in the spleen were observed at 22 and 45 hr post-intravenous injection, indicating clearance of yeasts from this tissue. By electron microscopy, C. albicans could only be demonstrated intracellularly in macrophages and neutrophils in the spleen removed 2 hr postinjection ( Fig. 4) . Thus, CFU count at 2 hr post-intravenous inoculation in the spleen was established as an optimal time point for screening a drug effect on phagocytosis. When a drug effect is evident on yeast uptake at 2 hr or survival time is decreased, the kinetics of CFUs in the spleen should be followed to further evaluate a potential effect on yeast killing reflected by its clearance from the spleen.
Effect of Immunosuppressive and Immunostimulating
Compounds on Nonspecific Immunity Assessment of drug effects on nonspecific immunity by CFU counts indicated that dexamethasone inhibited uptake of C. albicans by the spleen whereas cyclosporine did not. Both compounds, however, impaired clearance (Fig. 5 ). These results suggest that the immediate action of dexamethasone is due to inhibition of splenic neutrophil and macrophage phagocytosis of the yeast, while delayed effects of both compounds likely involve T-cell/macrophage interactions and, consequently, impair yeast killing. Liposomal MTP-PE, supprisingly, did not have a significant effect on spleen CFUs during the 45-hr period after challenge, although mean CFU count in spleens from MTP-PE-treated mice was lower than in the control group at 45 hr. Therefore, an additional time point of 70 hr was added and CFUs in the spleen and the kidney were determined. At that time, MTP-PE enhanced clearance of C. albicans from the spleen by 4-fold and limited colonization in the kidney (16-fold lower CFUs in comparison to control; Fig. 6A ). These data indicate a correlation between an increase in survival time (Fig. 2 ) and lower burden of yeast in kidney associated with MTP-PE administration. Treatment of mice with SK&F 105685 enhanced both uptake (CFUs at 2 hr) and clearance (CFUs at 45 hr) of C. albicans from the spleen (Fig. 6B ) by 100%, indicating an increase in phagocytosis of C. albicans and enhancement of yeast kill by splenic cells.
Cell-Mediated Immunity Model Injection of 1 X 106 C. albicans into the gastrocnemius muscle was not lethal, in comparison to intravenous inoculation, and mice substantially cleared this local infection in approximately 9 days. As shown in Fig. 7 , the decrease in muscle CFUs started on day 3 postinjection and progressed on days 6 and 9. Muscle CFUs on day 9 were 100-fold lower than on day 1. Histologically, on days 1 and 3 after an intramuscular injection of C. albicans, the muscle lesions were characterized by purulent myositis with abscess formation at the injection site. By day 3, some lesions were complicated by reactive fibroplasia and neovascularization (Fig.  FIG. 4. -Electron micrographs of C. albicans (arrows) in a neutrophil (PMN; A, magnification X 13,500; note pseudohyphal form of yeast) and in a macrophage (M; B, magnification X 10,000). Spleens were removed from mice 2 hr post-intravenous inoculation with I X 106 C. albicans. 8A). CD3 + T lymphocytes were a minority inflammatory cell in the inflammatory process of the day 3 lesion (Fig.  8B) . By day 6, the character of the muscle lesion had changed significantly. There was organization of the abscess into a chronic pyogranuloma . The skeletal muscle surrounding the pyogranuloma was characterized by edema, fibroplasia, neovascularization and infiltration of many lymphocytes and macrophages (Fig. 8C ). In contrast to the day 3 lesion, CD3+ T lymphocytes were a prominent component of the inflammatory process in the muscle tissue (Fig. 8D) . These data indicate a correlation between clearance of yeast from the muscle, measured by CFUs, and an involvement of T lymphocytes and cellular interactions typical of a cell-mediated immune response to infection, demonstrated histologically. Muscle CFU activity on day 6 post-intramuscular injection of C. albicans was thus designed a measure of CMI.
Effect of Immunosuppressive and Immunostimulating Compounds on Cell-Mediated Immunity
In the CMI model, both dexamethasone and cyclosporine inhibited the clearance of C. albicans from a localized infection in the calf muscle measured as 5-10fold increase in CFU counts, respectively (Fig. 9 ). These results are consistent with both anticipated suppression of T-cell functions by these compounds and involvement of T cell-mediated immunity in this model. In contrast, liposomal MTP-PE and SK&F 105685 had no effect on the clearance of C. albicans local infection from the muscle (data not shown), indicating that this model of CMI to C. albicans infection was not affected by these compounds.
HI Model
Mice were immunized with 2 injections of live C. albicans sc and sera were tested for specific anti-Candida antibody response by ELISA. In addition, skin samples taken on days 1, 8, and 15 from sites of subcutaneous injections were evaluated histologically. In general, the progress of the inflammatory process and the inflammatory exudate in this model paralleled that of the intramuscular model already described.
Effect of Immunosuppressive and Immunostimulating Compounds on HI
As demonstrated in Fig. 10 , in the HI response model, dexamethasone, cyclosporine, and SK&F 105685 decreased specific anti-Candida antibody production as measured by ELISA, whereas liposomal MTP-PE enhanced the anti-Candida antibody response. The effects of dexamethasone, cyclosporine, and SK&F 105685, on the one hand, and MTP-PE, on the other, are consistent with their known immunosuppressive and immunostimulating activities, respectively.
DISCUSSION
In this paper, we have described a new effector systems-based approach to immunotoxicologic evaluation of immunoactive agents on host defense against infection. The proposed model is designed to test overall immune function-NSI, HI, and CMI using a single infectious organism, Candida albicans, in an inbred strain of mice (CBA/J). Essential to the validity of our approach is that the models adequately measure effects on their respective effector systems, that is, that survival is in fact a measure of overall immunity, that splenic CFUs reflect NSI, and so forth. The tests performed to evaluate each effector arm are a general measure of their functionality, and we do not claim that they are, in rigorous terms, specific measures of these effector functions.
We chose C. albicans for both practical and scientific reasons. Practically, culturing and freezing stocks of C. albicans in the yeast form are straightforward and no special equipment is required, standardizing the inoculum is easy because the organism can be counted with a hemacytometer, CFUs can be read after 18 hr culture, and although C. albicans is capable of causing life-threatening disease it is a BL-2 rather than a BL-3 organism. Scientifically, C. albicans causes lethal infections in mice, making it useful for survival studies; it is also easy to culture from tissues, allowing CFUs to be measured, and there were data on the effects of immunologically active (both immunostimulant as well as immunosuppressive) drugs in C. albicans infections (23, 25, 32) .
Candida albicans was also chosen because it is an opportunistic pathogen in humans, causing infections in bums, transplantation, chemotherapy, and AIDS (35, 49, 66) . Moreover, there is ample experimental evidence that all effector arms of the immune system are involved in host defense against C. albicans. We chose the B311 isolate because of its long and widespread use in numerous laboratories and its availability to other investigators.
Having chosen C. albicans as a candidate test organism, we evaluated several strains of inbred mice as test FIG. 8.-Hematoxylin and eosin (H&E) and anti-CD3-stained serial sections of the gastrocnemius muscle on day 3 (A, B) and day 6 (C, D) following intramuscular inoculation with 1 X 106 organisms. Day 3 panels demonstrate a lesion with a prominent neutrophilic exudate and abcess (A) and few CD3+ cells (B). Day 6 panels depict a more chronic lesion with a pyogranulomatous exudate and fibroplasia (C) and numerous CD3+ T lymphocytes (D). Final magnification X 140. &dquo;species.&dquo; Mice were chosen because of the relatively large numbers of animals necessary to obtain statistically significant results in an inherently variable system. A survey of the literature showed that the majority of work with C. albicans had been conducted with BALB/c, C57B1/DBA2-F1, and CBA mice (3, 6, 14) . We evaluated these 3 strains and found that CBA/J mice provided a reproducible median survival time of 6 ± 2 days following intravenous injection of 1 X 106 organisms. A reproducible and relatively rapid outcome was necessary because we needed a standardized model that would be able to detect both immunosuppressive as well as immunostimulatory effects.
A test to evaluate spleen CFUs, as a measure of NSI, was chosen because the effector function of macrophages derived from spleen has been reported to be more efficient compared to other tissues, that is, only macrophages from liver and spleen displayed significant candidastatic activity (21) and only splenic macrophages, similarly to polymorphonuclear neutrophils, responded to both yeast and hyphal forms of C. albicans ( 15, 62) . That splenic CFUs are a measure of phagocytosis is supported by our electron microscopic data, which showed that 2 hr after injection C. albicans had been phagocytosed by macrophages or neutrophils. Furthermore, our data are consistent with studies on kinetics of C. albicans uptake by spleen and a role of splenic macrophages in host resistance to experimental disseminated candidiasis (52) . The delayed type hypersensitivity reaction of immunized mice to an intrafoot pad challenge with C. albicans is widely used as a surrogate measure of CMI (55) and yeast antigens are routinely used as &dquo;recall&dquo; antigens in clinical evaluation of CMI (29, 51) . Recently, Krause and Shaffner (37) have described a skin air pouch model of mucocutaneous candidaisis where host defense against C. albicans was shown to be dependent on CMI. Intramuscular injection of yeast has also been used to study immunological responses to C. albicans (47) . We have adapted the intramuscular injection approach as a model of CMI against C. albicans. Histologically, the host defense reaction to an intramuscular injection of yeast was characterized acutely by a neutrophilic inflammatory response as expected. Chronically, the identification of CD3 + cells in the exudate indicate a contribution of T lymphocytes in clearance of the inflammatory lesion in the skeletal muscle. As is well known, expression of CMI is dependent on expansion of antigen-specific T-cell clones and clonal expansion requires days to occur. Character of the tissue response on day 6 together with the CFU kinetics at the site of inoculation are highly suggestive that CMI plays an important role in the response to a localized, intramuscular infection by C. albicans and is consistent with published reports (2, 55) . HI plays what is generally believed to be a minor role in host defense to a primary infection with C. albicans (33) . Candiaisis is an uncommon finding in patients with defects in HI. While anti-Candida antibodies confer only partial protection against experimental challenge with C. albicans (46) , involvement of T helper cell subsets (Thl TABLE IL-Summary of drug effects on C. albicans host defense model. Symbols: .1 = decrease; T = increase; -= no effect. and Th2) in the regulation of both CMI and HI in response to the pathogen has been extensively studied in recent years. The connection between Th-type response and candidiasis outcome was elegantly demonstrated by Romani et al (54, 56) and Tonnetti et al (65) . In our model, to study the humoral response to a natural infection, measurement of the antibody production follows 2 subcutaneous inoculations with live C. albicans without adjuvant. Although, the anti-Candida-specific antibody response presents a relatively low titer and may have little beneficial impact on disease outcome, the ability to measure anti-Candida antibody serves as a good parameter of HI.
The results of our experiments with immunologically active compounds are summarized in Table II. Dexamethasone, like other steroid analogs, exerts broad-spectrum effects on immune function (19) . Thus, dexamethasone would be expected to inhibit NSI, CMI, HI, and overall immune function. Dexamethasone has been shown to inhibit phagocytosis and microbicidal activity of polymorphonuclear leukocytes and monocyte/ macrophages (13, 28) . These effects are consistent with our results on the effects of dexamethasone on uptake and elimination of C. albicans from the spleen. Dexamethasone has also been shown to inhibit CMI and lymphocyte functions by inhibiting production of multiple lymphokines (38) . Similarly, dexamethasone has been reported to cause a dose-dependent suppression of B-cell function (57, 58) . Thus, our findings with dexamethasone support the contention that all immune effector arms are affectedin response to C. albicans infection, and our test system can detect suppression of these functional activities.
Cyclosporine is a peptide-based natural product derived from the Tolypocladium inflatum fungus that is in wide clinical use in organ transplantation (17, 44, 50, 60) . Cyclosporine has been shown to be a potent inhibitor of CMI by inhibiting the early steps in T-lymphocyte activation (61, 68) . Thus, cyclosporine would be expected to exert its most potent effects on CMI. Our results in the muscle CFU assay showed that cyclosporine inhibited clearance of C. albicans from a localized infection. Similar results have been reported in a subcutaneous air pouch model of mucocutaneous C. albicans infection (37) . The spleen CFU model showed that while cyclosporine had no effect on the initial uptake it inhibited clearance of yeast from the spleen. We have also found that cyclosporine inhibited anti-Candida antibody production and decreased survival time. These effects are consistent with the inhibition of T-cell functions because they contribute to the efficiency of yeast clearance from the spleen (2) and provide help to HI against C. albicans (55) .
MTP-PE is a lipophilic analog of muramyl dipeptide (MDP, also referred to as adjuvant peptide), the smallest fragment of mycobacterial cell walls that retains adjuvant activity (24) . In addition to adjuvant activity, MDP analogs have been shown to activate microbicidal and tumoricidal activity of macrophages and to enhance survival in numerous models of infection (26, 36, 59) . Association of MTP-PE with negatively charged liposomes has been shown to dramatically enhance its activity (42) . Thus, liposomal MTP-PE would be expected to enhance survival and NSI. Our results with liposomal MTP-PE in the spleen CFU assay showed that it had no effect on the initial uptake of C. albicans but enhanced clearance from the spleen, suggesting an enhancement of yeast kill in the spleen. The enhanced killing in the spleen resulted in the lower burden of C. albicans in the kidney and, most likely, caused an increase in survival time. Protection against infection of C. albicans after treatment with muramyl peptides and correlation between their in vivo antiinfective activities and reticuloendothelial stimulating activity measured as clearance of colloidal carbon particles has been reported (27) . In other studies, however, phagocytosis of C. albicans was only slightly greater in cells from MDP-treated mice, whereas candidacidal activity of MDP-stimulated cells in vitro was 2 times higher than of cells from untreated mice (20) . These results suggest that muramyl peptide analogs effectively activate phagocytic cells in vitro, but whether rapid macrophage stimulation alone is responsible for antiinfective properties in vivo has not been determined. A lack of effect on phagocytosis in our study and yet increase in yeast clearance from tissues as well as in survival suggests that stimulation of secondary factors, that is, release of cytokines (tumor necrosis factor a and interferon ~y), may be a mode of liposomal MTP-PE action in NSI against C. albicans. Treatment with liposomal MTP-PE also enhanced an anti-Candida antibody response, indicating that liposomal MTP-PE is a potent stimulator of humoral response. Despite that mechanism of liposomal MTP-PE modulation of immune response to C. albicans has not been elucidated in depth, our findings with liposomal MTP-PE support its adjuvant properties with an ability to stimulate polyclonal activation (12) . SK&F 105685 is a macrophage targeting immunoregulatory azaspirane. Azaspiranes have been shown to have beneficial effects in a variety of animal models of autoimmune disease in rodents (7, 8) . Azaspiranes induce nonspecific suppressor cell activity across numerous species, including rats, mice, and dogs (9, 34) . SK&F 105685 was tested in the models of host defense against C. albicans to determine whether it could adversely affect host defense. Evaluation of SK&F 105685 demonstrated its differential effects on immunity. No effect on muscle CFUs was observed and, while there was decrease in anti-Candida antibody titer, this was contrasted by a strong enhancement of NSI and a moderate increase in survival time. The effects on anti-Candida antibody production were somewhat surprising. Previous studies with azaspiranes have shown that they have no effect on the antibody response to soluble protein antigens administered with complete Freund's adjuvant (10) . Our data suggest that while azaspiranes may have little or no inhibitory effects against a strong immunologic stimulus (i.e., ovalbumin in complete Frund's adjuvant) they can inhibit the response to a weak antigen (i.e., whole-cell C. albicans). The mechanism of this differential activity is unknown but may be related to an effect on antigen processing and/or presentation, consistent with the emerging profile of this compound as a modulator of different macrophage functions (10) . Nevertheless, our test system using model of host defense proved to be a sensitive tool allowing differentiation between compounds that are selectively immunoregulatory as part of their pharmacology, that is, SK&F 105685, and the more broadly immunosuppressive agents such as steroids.
In conclusion, we propose that a series of models using a single infectious organism provide a useful method for evaluating the effects of immunologically active drugs on host defense. This approach, emphasizing the contribution of the different effector arms of the immune network, has an advantage over the traditional multiorganism approach. Moreover, because the approach addresses host defense directly, the investigator is not faced with the difficulty of extrapolating human risk from ultrasensitive surrogate markers of immune function. Finally, because the models are run over 14 days, the data are readily integrated with general toxicology findings.
